BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nakajo M, Nakajo M, Kajiya Y, Jinguji M, Nishimata N, Shimaoka S, Nihara T, Aridome K, Tanaka S, Fukukura Y, Tani A, Koriyama C. Diagnostic performance of 18F-fluorothymidine PET/CT for primary colorectal cancer and its lymph node metastasis: comparison with 18F-fluorodeoxyglucose PET/CT. Eur J Nucl Med Mol Imaging 2013;40:1223-32. [DOI: 10.1007/s00259-013-2424-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Beheshti M, Rezaee A, Herrmann K, Raderer M, Langsteger W. Colorectal Cancer. PET/CT in Cancer: An Interdisciplinary Approach to Individualized Imaging. Elsevier; 2018. pp. 111-25. [DOI: 10.1016/b978-0-323-48567-8.00006-7] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Nakajo M, Kajiya Y, Tani A, Jinguji M, Nakajo M, Yoshiura T. FLT-PET/CT diagnosis of primary and metastatic nodal lesions of gastric cancer: comparison with FDG-PET/CT. Abdom Radiol (NY) 2016;41:1891-8. [PMID: 27255652 DOI: 10.1007/s00261-016-0788-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
3 Kim JE, Chae SY, Kim JH, Kim HJ, Kim TW, Kim K, Kim SY, Lee J, Oh SJ, Kim JS, Ryu J, Moon DH, Hong YS. 3′-Deoxy-3’-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies. Eur J Nucl Med Mol Imaging 2019;46:1713-22. [DOI: 10.1007/s00259-019-04330-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
4 Jiang L, Tu Y, Shi H, Cheng Z. PET probes beyond (18)F-FDG. J Biomed Res 2014;28:435-46. [PMID: 25469112 DOI: 10.7555/JBR.28.20130196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
5 Rayamajhi SJ, Mittal BR, Maturu VN, Agarwal R, Bal A, Dey P, Shukla J, Gupta D. 18F-FDG and 18F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes. Ann Nucl Med 2016;30:207-16. [DOI: 10.1007/s12149-015-1047-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
6 Nakajo M, Kajiya Y, Tani A, Jinguji M, Nakajo M, Nihara T, Fukukura Y, Yoshiura T. A pilot study of the diagnostic and prognostic values of FLT-PET/CT for pancreatic cancer: comparison with FDG-PET/CT. Abdom Radiol (NY) 2017;42:1210-21. [PMID: 27891549 DOI: 10.1007/s00261-016-0987-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Nakajo M, Kajiya Y, Jinguji M, Nakabeppu Y, Nakajo M, Nihara T, Yoshiura T. Current clinical status of 18F-FLT PET or PET/CT in digestive and abdominal organ oncology. Abdom Radiol (NY) 2017;42:951-61. [PMID: 27770160 DOI: 10.1007/s00261-016-0947-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
8 Nakajo M, Nakajo M, Kajiya Y, Goto Y, Jinguji M, Tanaka S, Fukukura Y, Tani A, Higashi M. Correlations of (18)F-fluorothymidine uptake with pathological tumour size, Ki-67 and thymidine kinase 1 expressions in primary and metastatic lymph node colorectal cancer foci. Eur Radiol 2014;24:3199-209. [PMID: 25120206 DOI: 10.1007/s00330-014-3379-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 García-Figueiras R, Baleato-González S, Padhani AR, Luna-Alcalá A, Marhuenda A, Vilanova JC, Osorio-Vázquez I, Martínez-de-Alegría A, Gómez-Caamaño A. Advanced Imaging Techniques in Evaluation of Colorectal Cancer. Radiographics 2018;38:740-65. [PMID: 29676964 DOI: 10.1148/rg.2018170044] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]